HLA‐E polymorphism and soluble HLA‐E plasma levels in chronic hepatitis B patients. (8th March 2016)

• Record Type: Journal Article
• Authors: Zidi, I.; Laaribi, A. B.; Bortolotti, D.; Belhadj, M.; Mehri, A.; Yahia, H. B.; Babay, W.; Chaouch, H.; Zidi, N.; Letaief, A.; Yacoub, S.; Boukadida, J.; Di Luca, D.; Hannachi, N.; Rizzo, R.
• Is Part Of: HLA. Volume 87:Number 3(2016)
• Page Start: 153
• Page End: 159
• Publication Date: 2016-03-08
• Subjects: chronic hepatitis B -- human leukocyte antigen‐E gene -- polymorphism -- soluble human leukocyte antigen‐E; Immunogenetics -- Periodicals; Antigens -- Periodicals; HLA histocompatibility antigens -- Periodicals; 571.9645
• DOI: 10.1111/tan.12767
• Languages: English
• ISSNs: 2059-2302

Abstract

Abstract: Chronic hepatitis B virus (HBV) infection occurs in association to a deregulation of immune system. Human leukocyte antigen E (HLA‐E) is an immune‐tolerant nonclassical HLA class I molecule that could be involved in HBV progression. To measure soluble (s) HLA‐E in patients with chronic HBV hepatitis (CHB). We tested the potential association of HLA‐E*01:01/01:03 A > G gene polymorphism to CHB. Our cohort consisted of 93 Tunisian CHB patients (stratified in CHB with high HBV DNA levels and CHB with low HBV DNA levels) and 245 healthy donors. Plasma sHLA‐E was determined using enzyme‐linked immunosorbent assay (ELISA). Genotyping was performed using polymerase chain reaction sequence‐specific primer. No association between HLA‐E*01:01/01:03 A > G polymorphism and HBV DNA levels in CHB patients was found. G/G genotype is less frequent in CHB patients without significance. sHLA‐E is significantly enhanced in CHB patients compared with healthy controls ( P = 0.0017). Stratification according to HBV DNA levels showed that CHB patients with low HBV DNA levels have higher sHLA‐E levels compared with CHB patients with high HBV DNA levels. CHB patients with G/G genotype have enhanced sHLA‐E levels compared with other genotypes ( P = 0.037). This significant difference is maintained only for CHB women concerning G/G genotypes ( P = 0.042). Finally, we reported enhanced sHLA‐E in CHB patients with advanced stages of fibrosis ( P = 0.032). We demonstrate, for the first time, the association of sHLA‐E to CHB. Owing to the positive correlation of HLA‐E*01:01/01:03 A > G polymorphism and the association of sHLA‐E to advanced fibrosis stages, HLA‐E could be a powerful predictor for CHB progression. Further investigations will be required to substantiate HLA‐E role as a putative clinical biomarker of CHB.